Asieris Pharmaceuticals announced on the evening of October 7 that it has signed a conditional exclusive licensing agreement with Theramex HQ UK Limited. Theramex will obtain exclusive rights to APL-1702, marketed as CEVIRA, in European countries as well as Australia, New Zealand and Turkey, while the company retains related rights in the rest of the world. Under the agreement, the company will receive an upfront payment of 15 million US dollars, a near-term regulatory milestone payment of 11 million US dollars, as well as commercial milestone payments and tiered sales royalties, bringing the total transaction value to more than 250 million US dollars. The announcement showed that CEVIRA is a first-in-class photodynamic therapy product, consisting of hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic therapy light device, achieving a breakthrough in treatment through innovative local administration and an intravaginal cold light source design. The product offers unique advantages in treatment, including precise targeted clearance of lesions, immune clearance of HPV, and protection of fertility.
Jiangsu Yahong Meditech Co. Ltd.Signs exclusive licensing deal with Theramex for APL-1702 (CEVIRA) in Europe/Australia/NZ/Turkey, worth over $250M in upfront, milestone and royalty payments.
Obtains exclusive rights to commercialize APL-1702 (CEVIRA) across European countries, Australia, New Zealand and Turkey.
